{"id":"NCT02737501","sponsor":"Ariad Pharmaceuticals","briefTitle":"ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants","officialTitle":"A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-26","primaryCompletion":"2020-07-28","completion":"2021-01-29","firstPosted":"2016-04-14","resultsPosted":"2021-08-20","lastUpdate":"2021-08-20"},"enrollment":275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-small Cell Lung Cancer","Lung Cancer","Advanced Malignancies","Carcinoma"],"interventions":[{"type":"DRUG","name":"Brigatinib","otherNames":[]},{"type":"DRUG","name":"Crizotinib","otherNames":["Xalkori"]}],"arms":[{"label":"Randomized Phase: Brigatinib 90 mg QD/180 QD","type":"EXPERIMENTAL"},{"label":"Randomized Phase: Crizotinib 250 mg BID","type":"ACTIVE_COMPARATOR"},{"label":"Crossover Phase: Brigatinib 90 mg QD/180 mg QD","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to compare the efficacy of brigatinib to that of crizotinib in ALK+ locally advanced or metastatic non-small cell lung cancer (NSCLC) participants naive to ALK inhibitors, as evidenced by progression-free survival (PFS).","primaryOutcome":{"measure":"Progression-free Survival (PFS)","timeFrame":"Up to end of study (Up to 56 months)","effectByArm":[{"arm":"Randomized Phase: Brigatinib 90 mg QD/180 QD","deltaMin":24.016,"sd":null},{"arm":"Randomized Phase: Crizotinib 250 mg BID","deltaMin":11.072,"sd":null},{"arm":"Crossover Phase: Brigatinib 90 mg QD/180 mg QD","deltaMin":16.821,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":91,"countries":["United States","Australia","Austria","Canada","Denmark","France","Germany","Hong Kong","Italy","Luxembourg","Netherlands","Norway","Singapore","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["39707229","32780660","30280657","28501139"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":136},"commonTop":["Diarrhoea","Nausea","Blood Creatine Phosphokinase Increased","Vomiting","Cough"]}}